The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...